CA2284829A1 - Immunotherapy of b-cell malignancies using anti-cd22 antibodies - Google Patents

Immunotherapy of b-cell malignancies using anti-cd22 antibodies Download PDF

Info

Publication number
CA2284829A1
CA2284829A1 CA002284829A CA2284829A CA2284829A1 CA 2284829 A1 CA2284829 A1 CA 2284829A1 CA 002284829 A CA002284829 A CA 002284829A CA 2284829 A CA2284829 A CA 2284829A CA 2284829 A1 CA2284829 A1 CA 2284829A1
Authority
CA
Canada
Prior art keywords
antibody
group
immunoconjugate
conjugated
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002284829A
Other languages
French (fr)
Other versions
CA2284829C (en
Inventor
David M. Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21916876&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2284829(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2284829A1 publication Critical patent/CA2284829A1/en
Application granted granted Critical
Publication of CA2284829C publication Critical patent/CA2284829C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

B-Cell malignacies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.

Claims (39)

1. Use of at least one entire anti-CD22 antibody that is not conjugated to a therapeutic agent, in the preparation of a medicament for use in a method of treating a B-cell malignancy, wherein, in said method, a subject having a B-cell malignancy is administered a therapeutically effective amount of the entire anti-CD22 antibody that is not conjugated to a therapeutic agent.
2. Use of at least one entire anti-CD22 antibody that is not conjugated to a therapeutic agent, in treating a B-cell malignancy.
3. A method for treating a B-cell malignancy, comprising the step of administering to a subject having a B-cell malignancy a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one entire anti-CD22 antibody that is not conjugated to a therapeutic agent.
4. The use of claim 1 or 2, or the method of claim 3, wherein said anti-CD22 antibody is parenterally administered in a dosage of 20 to 100 milligrams protein per dose.
5. The use of claim 1 or 2, or the method of claim 3, wherein a subject receives anti-CD22 antibody as repeated parenteral dosages of 20 to 100 milligrams protein per dose.
6. The use of claim 1 or 2, or the method of claim 3, wherein said anti-CD22 antibody is selected from the group consisting of subhuman primate antibody, murine monoclonal antibody, chimeric antibody, and humanized antibody.
7. The use of claim 1 or 2, or the method of claim 3, wherein said anti-CD22 antibody is the LL2 antibody.
8. The use of claim 1 or 2, or the method of claim 3, wherein said B-cell malignancy is selected from the group consisting of indolent forms of B-cell lymphomas, aggressive forms of B-cell lymphomas, chronic lymphatic leukemias, and acute lymphatic leukemias.
9. The use of claim 1 or 2, or the method of claim 3, wherein said B-cell malignancy is a non-Hodgkin's lymphoma.
10. The method of claim 3, wherein said therapeutic composition comprises at least two monoclonal antibodies that bind with distinct CD22 epitopes, wherein said CD22 epitopes are selected from the group consisting of epitope A, epitope B, epitope C, epitope D and epitope E.
11. The method of claim 3, further comprising the step of administering a therapeutic protein or chemotherapeutic treatment, wherein said therapeutic protein is selected from the group consisting of antibody, immunoconjugate, antibody-immunomodulator fusion protein and antibody-toxin fusion protein.
12. The method of claim 11, wherein said therapeutic protein or said chemotherapeutic treatment is administered prior to the administration of said anti-CD22 antibody.
13. The method of claim 11, wherein said therapeutic protein or said chemotherapeutic treatment is administered concurrently with the administration of said anti-CD22 antibody.
14. The method of claim 11, wherein said therapeutic protein or said chemotherapeutic treatment is administered after the administration of said anti-CD22 antibody.
15. The method of claim 11, wherein said chemotherapeutic treatment consists of the administration of at least one drug selected from the group consisting of cyclophosphamide, etoposide, vincristine, procarbazine, prednisone, carmustine, doxorubicin, methotrexate, bleomycin, dexamethasone, phenyl butyrate, brostatin-1 and leucovorin.
16. The method of claim 11, wherein said therapeutic protein is either an entire anti-CD19 antibody that is not conjugated to a therapeutic agent or an entire anti-CD20 antibody that is not conjugated to a therapeutic agent.
17. The method of claim 11, wherein said therapeutic protein is a radiolabeled immunoconjugate.
18. The method of claim 17, wherein said radiolabeled immunoconjugate comprises a radionuclide selected from the group ~
consisting of 198Au, 32P, 125I, 131I, 90Y, 186Re, 188Re, 67Cu, and 211At.
19. The method of claim 18, wherein said radiolabeled immunoconjugate comprises an antibody or antibody fragment that binds an antigen selected from the group consisting of CD19, CD20 and CD22.
20. The method of claim 19, wherein said radiolabeled immunoconjugate is a radiolabeled anti-CD22 immunoconjugate.
21. The method of claim 20, wherein said radiolabeled anti-CD22 immunoconjugate further comprises a cytokine moiety, wherein said cytokine moiety is selected from the group consisting of interleukin-1 (IL-1), IL-2, IL-3, IL-6, IL-10, IL-12, interferon-.alpha., interferon-.beta., and interferon-.gamma..
22. The method of claim 11, wherein said therapeutic protein is an immunoconjugate or antibody-toxin fusion protein that comprises a toxin selected from the group consisting of ricin, abrin, ribonuclease, DNase I, Staphylococcal enterotoxin-A, pokeweed antiviral protein, gelonin, diphtherin toxin, Pseudomonas exotoxin, and Pseudomonas endotoxin.
23. The method of claim 22, wherein said immunoconjugate or said antibody-toxin fusion protein comprises an antibody or antibody fragment that binds an antigen selected from the group consisting of CD19, CD20 and CD22.
24. The method of claim 11, wherein said therapeutic protein is an immunoconjugate or a fusion protein, wherein said immunoconjugate or fusion protein comprises an immunomodulator moiety selected from the group consisting of interleukin-1 (IL-1), IL-2, IL-3, IL-6 and IL-10, IL-12, interferon-.alpha., interferon-.beta., interferon-.gamma., granulocyte-colony stimulating factor, granulocyte macrophage-colony stimulating factor and lymphotoxin.
25. The method of claim 24, wherein said immunoconjugate or said antibody-immunomodulator fusion protein binds an antigen selected from the group consisting of CD19, CD20 and CD22.
26. A method for treating a B-cell malignancy as claimed in claim 3, wherein said therapeutic composition comprises a combination of at least one entire anti-CD22 antibody that is not conjugated to a therapeutic agent and an anti-CD19 antibody, a combination of at least one entire anti-CD22 antibody that is not conjugated to a therapeutic agent and an anti-CD20 antibody, or a combination of at least one entire anti-CD22 antibody that is not conjugated to a therapeutic agent, an anti-CD19 antibody and an anti-CD20 antibody.
27. The method of claim 26, wherein said anti-CD19 antibody is an entire anti-CD19 antibody that is not conjugated to a therapeutic agent.
28. The method of claim 26, wherein said anti-CD20 antibody is an entire anti-CD20 antibody that is not conjugated to a therapeutic agent.
29. The method of claim 17, wherein said radiolabeled anti-CD22 immunoconjugate further comprises a colony stimulating factor, wherein said colony stimulating factor is selected from the group consisting of granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage-colony stimulating factor (GM-CSF).
30. The use of claim 1 or 2, where said anti-CD22 antibody has the antigen-binding specificity of the LL2 antibody.
31. The use of claim 1 or 2, wherein said therapeutic composition comprises at least two monoclonal antibodies that bind with distinct CD22 epitopes, wherein said CD22 epitopes are selected from the group consisting of epitope A, epitope B, epitope C, epitope D and epitope E.
32. The use of claim 1 or 2, wherein said B-cell malignancy is selected from the group consisting of indolent forms of B-cell lymphomas, aggressive forms of B-cell lymphomas, chronic lymphatic leukemias, and acute lymphatic leukemias.
33. The use of claim 1 or 2, further comprising the step of administering a therapeutic protein or chemotherapeutic treatment, wherein said therapeutic protein is selected from the group consisting of antibody, immunoconjugate, antibody-immunomodulator fusion protein and antibody-toxin fusion protein.
34. The use of claim 33, wherein said therapeutic protein is either an anti-CD19 antibody or an CD20 antibody.
35. The use of claim 34, wherein said anti-CD19 antibody is an entire anti-CD19 antibody that is not conjugated to a therapeutic agent and said anti-CD20 antibody is an entire CD20 antibody that is not conjugated to a therapeutic agent.
36. The use of claim 33, wherein said therapeutic protein is a combination of at least one anti-CD19 antibody and at least one anti-CD20 antibody.
37. The use of claim 36, wherein said anti-CD19 antibody is an entire anti-CD19 antibody that is not conjugated to a therapeutic agent and said anti-CD20 antibody is an entire CD20 antibody that is not conjugated to a therapeutic agent.
38. The use of claim 33, wherein said therapeutic protein is an immunoconjugate or a fusion protein, wherein said immunoconjugate or fusion protein comprises an immunomodulator moiety selected from the group consisting of interleukin-1 (IL-1), Il-2, IL-3, Il-6 and IL-10, IL-12, interferon-.alpha., interferon-.beta., interferon-.gamma., granulocyte-colony stimulating factor, granulocyte macrophage-colony stimulating factor and lymphotoxin.
39. The use of claim 33, wherein said immunoconjugate comprises a colony stimulating factor selected from the group consisting of granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage-colony stimulating factor (GM-CSF).
CA2284829A 1997-03-24 1998-03-17 Immunotherapy of b-cell malignancies using anti-cd22 antibodies Expired - Lifetime CA2284829C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4150697P 1997-03-24 1997-03-24
US60/041,506 1997-03-24
PCT/US1998/005075 WO1998042378A1 (en) 1997-03-24 1998-03-17 Immunotherapy of b-cell malignancies using anti-cd22 antibodies

Publications (2)

Publication Number Publication Date
CA2284829A1 true CA2284829A1 (en) 1998-10-01
CA2284829C CA2284829C (en) 2012-10-23

Family

ID=21916876

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2284829A Expired - Lifetime CA2284829C (en) 1997-03-24 1998-03-17 Immunotherapy of b-cell malignancies using anti-cd22 antibodies

Country Status (12)

Country Link
US (1) US6183744B1 (en)
EP (4) EP1431311B1 (en)
JP (2) JP4584363B2 (en)
AT (1) ATE297759T1 (en)
AU (1) AU728325B2 (en)
CA (1) CA2284829C (en)
DE (1) DE69830570T3 (en)
DK (1) DK0969866T4 (en)
ES (1) ES2241129T5 (en)
IN (1) IN189313B (en)
WO (1) WO1998042378A1 (en)
ZA (1) ZA982438B (en)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
DE122004000036I1 (en) * 1992-11-13 2005-07-07 Biogen Idec Inc Therapeutic use of chimeric and labeled antibodies to human B lymphocyte limited differentiation antigen for the treatment of B-cell lymphoma.
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
ES2285720T3 (en) * 1997-12-16 2007-11-16 University Of Zurich METHOD OF MANUFACTURE OF THERAPEUTIC PRODUCTS FOR TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY, BLOOD PRODUCTS AND NON-INFECTIOUS FABRICS AND METHODS FOR OBTAINING IT.
ES2434961T5 (en) * 1998-04-20 2018-01-18 Roche Glycart Ag Antibody glycosylation engineering to improve antibody-dependent cell cytotoxicity
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
NZ528199A (en) 1998-08-11 2005-06-24 Idec Pharma Corp Combination therapies for B-cell lyphomas comprising administration of anti-CD20 antibody
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
ES2338287T3 (en) * 1998-11-09 2010-05-05 Biogen Idec Inc. TREATMENT OF ANTI-CD20 PATIENTS ANTIBODIES RECEIVING TRANSPLANTS OF OSEA MEDULA GRAFT OR MOTHER PERIPHERAL BLOOD CELLS.
AU761844C (en) * 1998-11-09 2004-09-23 F. Hoffmann-La Roche Ag Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
CA2363568A1 (en) * 1999-03-04 2000-09-08 Kyowa Hakko Kogyo Co., Ltd. Diagnostic agent and therapeutic agent for leukemia
US7696325B2 (en) * 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
WO2000063719A1 (en) * 1999-04-20 2000-10-26 Synthes Ag Chur Device for the percutaneous obtainment of 3d-coordinates on the surface of a human or animal organ
EP1642596A3 (en) * 1999-05-07 2006-04-12 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8383081B2 (en) * 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US6451284B1 (en) * 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US20030143234A1 (en) * 1999-08-20 2003-07-31 Wenyuan Shi Anti-microbial targeting chimeric pharmaceutical
US7569542B2 (en) 1999-08-20 2009-08-04 The Regents Of The University Of California Anti-microbial targeting chimeric pharmaceutical
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020006404A1 (en) * 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
MXPA02009626A (en) * 2000-03-31 2003-05-14 Idec Pharma Corp Combined use of anti cytokine antibodies or antagonists and anti cd20 for the treatment of b cell lymphoma.
AU2001268363B2 (en) 2000-06-20 2006-08-17 Biogen Idec Inc. Treatment of B cell associated diseases
AU7013401A (en) * 2000-06-22 2002-01-02 Univ Iowa Res Found Methods for enhancing antibody-induced cell lysis and treating cancer
MXPA03002262A (en) * 2000-09-18 2003-10-15 Idec Pharma Corp Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination.
US8034903B2 (en) * 2000-10-20 2011-10-11 Chugai Seiyaku Kabushiki Kaisha Degraded TPO agonist antibody
US20040242847A1 (en) * 2000-10-20 2004-12-02 Naoshi Fukushima Degraded agonist antibody
WO2002034790A1 (en) * 2000-10-20 2002-05-02 Idec Pharmaceuticals Corporation Variant igg3 rituxan r and therapeutic use thereof
CN1494553A (en) * 2001-01-29 2004-05-05 IDECҩ�﹫˾ Modified antibodies and method of use
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
WO2002080987A1 (en) * 2001-04-09 2002-10-17 Progenics Pharmaceuticals, Inc. Anti-cd19 immunotoxins
EP1387697A4 (en) * 2001-05-17 2005-04-20 Jolla Pharma Methods of treating antibody-mediated pathologies using agents which inhibit cd21
US20020193569A1 (en) * 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
AU2002315168A1 (en) * 2001-06-14 2003-01-02 Intermune, Inc. Combination therapy of gamma-interferon and b cell specific antibodies
KR20100018071A (en) * 2001-08-03 2010-02-16 글리카트 바이오테크놀로지 아게 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
IL162732A0 (en) * 2001-12-26 2005-11-20 Immunomedics Inc Methods of generating multispecific, multivalent agents from hv and vl domains
US8287864B2 (en) * 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
CN100522999C (en) * 2002-02-14 2009-08-05 免疫医疗公司 Anti-CD20 antibodies and fusion proteins thereof and methods of use
WO2003072736A2 (en) * 2002-02-21 2003-09-04 Duke University Reagents and treatment methods for autoimmune diseases
US7238785B2 (en) * 2002-03-01 2007-07-03 Immunomedics, Inc. RS7 antibodies
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US9745380B2 (en) 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
CN100482277C (en) 2002-05-02 2009-04-29 惠氏控股公司 Calicheamicin derivative-carrier conjugates
AU2012244218C1 (en) * 2002-05-02 2016-12-15 Wyeth Holdings Llc. Calicheamicin derivative-carrier conjugates
AU2003241024A1 (en) * 2002-05-29 2003-12-19 Immunomedics, Inc. Methods and compositions for radioimmunotherapy of brain and cns tumors
ATE414105T1 (en) * 2002-10-11 2008-11-15 Chugai Pharmaceutical Co Ltd CELL DEATH-INDUCING AGENT
CA3029035C (en) * 2002-10-17 2023-03-07 Genmab A/S Human monoclonal antibodies against cd20
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
US7534431B2 (en) * 2003-01-31 2009-05-19 Immunomedics, Inc. Methods and compositions for administering therapeutic and diagnostic agents
WO2004074318A2 (en) 2003-02-24 2004-09-02 Institut Pasteur Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof.
JP2004279086A (en) * 2003-03-13 2004-10-07 Konica Minolta Holdings Inc Radiation image conversion panel and method for manufacturing it
JPWO2004087763A1 (en) * 2003-03-31 2006-07-27 中外製薬株式会社 Modified antibody against CD22 and use thereof
WO2004111233A1 (en) * 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha Process for producing antibody
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
JP4733635B2 (en) * 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド Anti-CD19 antibody
WO2005014618A2 (en) * 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
BR122018071808B8 (en) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
US20070281327A1 (en) * 2003-12-12 2007-12-06 Kiyotaka Nakano Methods of Screening for Modified Antibodies With Agonistic Activities
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US7875598B2 (en) * 2004-03-04 2011-01-25 The Regents Of The University Of California Compositions useful for the treatment of microbial infections
US20080274110A1 (en) * 2004-04-09 2008-11-06 Shuji Ozaki Cell Death-Inducing Agents
WO2005115477A2 (en) 2004-04-13 2005-12-08 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
WO2005103081A2 (en) * 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
JP5055603B2 (en) 2004-08-04 2012-10-24 メントリック・バイオテック・リミテッド・ライアビリティ・カンパニー Mutated Fc region
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
JP5057967B2 (en) 2005-03-31 2012-10-24 中外製薬株式会社 sc (Fv) 2 structural isomer
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
DK1874821T3 (en) 2005-04-26 2013-07-08 Trion Pharma Gmbh Combination of antibodies with glycocorticoids to treat cancer
CA2607256A1 (en) 2005-05-02 2006-11-09 Cold Spring Harbor Laboratory Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
EP1927367A4 (en) * 2005-05-18 2009-08-12 Univ Tokushima Novel pharmaceutical using anti-hla antibody
KR101367544B1 (en) * 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 Stabilizer for protein preparation comprising meglumine and use thereof
JP5085322B2 (en) 2005-06-10 2012-11-28 中外製薬株式会社 Pharmaceutical composition containing sc (Fv) 2
WO2006132341A1 (en) * 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 SITE-DIRECTED MUTANT
KR20080025174A (en) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 Antibody formulations having optimized aggregation and fragmentation profiles
US20070190047A1 (en) * 2005-07-29 2007-08-16 Amgen, Inc. Formulations that inhibit protein aggregation
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP2650306A1 (en) 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP1998799B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CA2650730A1 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
US20100040600A1 (en) * 2006-06-14 2010-02-18 Chugai Seiyaku Kabushiki Kaisha Agents for Promoting the Growth of Hematopoietic Stem Cells
JP2009541333A (en) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド Modified ribonuclease
US20100150927A1 (en) * 2006-07-13 2010-06-17 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
EP2049151A4 (en) 2006-07-17 2010-03-24 Quintessence Biosciences Inc Methods and compositions for the treatment of cancer
JP5775260B2 (en) 2006-09-06 2015-09-09 シー３ ジアン インコーポレイテッド Selectively targeted antimicrobial peptides and uses thereof
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034076A2 (en) * 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
NZ578064A (en) 2006-12-01 2012-01-12 Medarex Inc Human antibodies that bind cd22 and uses thereof
KR20150038227A (en) 2007-01-16 2015-04-08 애브비 인코포레이티드 Methods for treating psoriasis
CL2008000719A1 (en) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku THERAPEUTIC AGENT FOR CANCER RESISTANT TO CHEMOTHERAPEUTIC AGENTS THAT UNDERSTAND AN ANTIBODY THAT RECOGNIZES IT CLASS I AS ACTIVE INGREDIENT; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH ANTIBODY; AND METHOD TO TREAT CANCER RESISTANT TO
CN101679507A (en) 2007-03-29 2010-03-24 艾博特公司 crystalline anti-human il-12 antibodies
SG183044A1 (en) 2007-07-16 2012-08-30 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugatesand methods of use
ES2381788T3 (en) 2007-07-16 2012-05-31 Genentech, Inc. Anti-CD79b and immunoconjugate antibodies and methods of use
JP2010540681A (en) * 2007-10-08 2010-12-24 クインテッセンス バイオサイエンシズ，インコーポレーテッド Compositions and methods for ribonuclease based therapy
US9026372B2 (en) 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
UA106586C2 (en) 2008-01-31 2014-09-25 Дженентек, Інк. Anti-cd79b antibodies and imunokonugate and methods for their use
BRPI0908715A2 (en) 2008-03-18 2016-05-03 Abbott Lab Methods for psoriasis treatment
CN102159243B (en) * 2008-07-21 2015-08-19 免疫医疗公司 For the structural variant of the antibody for the treatment of feature improved
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
JP2012504423A (en) 2008-10-01 2012-02-23 クインテッセンス バイオサイエンシズ，インコーポレーテッド Therapeutic ribonuclease
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP3939617A1 (en) 2009-02-13 2022-01-19 Immunomedics, Inc. Conjugates with an intracellularly-cleavable linkage
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
KR20120104517A (en) * 2009-09-03 2012-09-21 제넨테크, 인크. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
IN2012DN03354A (en) 2009-12-02 2015-10-23 Immunomedics Inc
EP2523680A4 (en) * 2010-01-11 2013-06-19 Ct Molecular Med & Immunology Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
CA2789629A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc. Cd20 antibodies and uses thereof
CA2824143C (en) 2011-01-14 2018-12-18 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
RU2013140975A (en) 2011-02-28 2015-04-10 Дженентек, Инк. BIOLOGICAL MARKERS AND METHODS FOR PREDICTING SUSCEPTIBILITY TO B-CELL ANTAGONISTS
CN107115526A (en) 2011-05-02 2017-09-01 免疫医疗公司 The ultrafiltration concentration of the antibody for the allograft selection applied for small size
WO2013085893A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US9757458B2 (en) * 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
GB201201062D0 (en) 2012-01-23 2012-03-07 Ge Healthcare Ltd Radiofluorination method
AU2013290424B2 (en) 2012-07-19 2018-01-25 Redwood Bioscience, Inc. Antibody specific for CD22 and methods of use thereof
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
CA2874864C (en) 2012-08-14 2023-02-21 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
CA2884313C (en) 2012-12-13 2023-01-03 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
GB201308053D0 (en) 2013-05-03 2013-06-12 Ge Healthcare Ltd Metal complexes and fluorination thereof
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
PT3050896T (en) 2013-09-27 2021-08-24 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
MX2016010683A (en) 2014-02-21 2017-05-11 Ibc Pharmaceuticals Inc Disease therapy by inducing immune response to trop-2 expressing cells.
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
CA2953567C (en) 2014-06-24 2023-09-05 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
EP3689910A3 (en) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
CN106999517A (en) 2014-10-07 2017-08-01 免疫医疗公司 The new adjuvant purposes of antibody drug conjugate
CN107249633A (en) 2014-12-19 2017-10-13 迈博太科公司 For composition, kit and the method for the people's cell activation for suppressing the mediations of IL 21
CN107428837A (en) 2015-04-22 2017-12-01 免疫医疗公司 Circulate separation, detection, diagnosis and/or the identification of the positive cancer cells of TROP 2
PL3313443T3 (en) 2015-06-25 2023-11-06 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of fc region-containing polypeptide
US20170224837A1 (en) 2016-02-10 2017-08-10 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
EP3448260A4 (en) 2016-04-27 2019-10-09 Immunomedics, Inc. Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
WO2018112407A1 (en) 2016-12-15 2018-06-21 Duke University Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors
US10918734B2 (en) 2017-03-27 2021-02-16 Immunomedics, Inc. Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
WO2021246637A1 (en) 2020-06-01 2021-12-09 주식회사 이노베이션바이오 Antibody specific to cd22, and use thereof
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
KR102393776B1 (en) 2020-12-30 2022-05-04 (주)이노베이션바이오 Humanized antibody specific for CD22 and chimeric antigen receptor using the same
EP4342497A1 (en) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antibody having reduced binding affinity for antigen

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4624846A (en) 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
ATE149841T1 (en) 1990-01-26 1997-03-15 Immunomedics Inc VACCINES AGAINST CANCER AND INFECTIOUS DISEASES
JPH05344899A (en) * 1992-06-11 1993-12-27 Kokuritsu Yobou Eisei Kenkyusho Production of coat protein of hepatitis c virus
DE122004000036I1 (en) * 1992-11-13 2005-07-07 Biogen Idec Inc Therapeutic use of chimeric and labeled antibodies to human B lymphocyte limited differentiation antigen for the treatment of B-cell lymphoma.
US5484892A (en) 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
WO1996004925A1 (en) * 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
WO1998041641A1 (en) * 1997-03-20 1998-09-24 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors
ATE477276T1 (en) * 2002-03-01 2010-08-15 Immunomedics Inc INTERNALIZATION OF ANTI CD74 MONOCLONAL ANTIBODIES AND THEIR USES

Also Published As

Publication number Publication date
EP0969866A1 (en) 2000-01-12
DK0969866T3 (en) 2005-10-03
JP2010031032A (en) 2010-02-12
EP1459768A3 (en) 2008-10-15
EP1459768A2 (en) 2004-09-22
CA2284829C (en) 2012-10-23
ATE297759T1 (en) 2005-07-15
JP2001518930A (en) 2001-10-16
DK0969866T4 (en) 2009-03-30
ZA982438B (en) 1998-11-04
EP0969866B2 (en) 2009-02-18
AU6761098A (en) 1998-10-20
DE69830570D1 (en) 2005-07-21
ES2241129T3 (en) 2005-10-16
IN189313B (en) 2003-02-08
JP4584363B2 (en) 2010-11-17
WO1998042378A1 (en) 1998-10-01
AU728325B2 (en) 2001-01-04
EP1431311A1 (en) 2004-06-23
US6183744B1 (en) 2001-02-06
DE69830570T3 (en) 2009-09-03
DE69830570T2 (en) 2005-11-03
EP0969866B1 (en) 2005-06-15
EP2332576A1 (en) 2011-06-15
ES2241129T5 (en) 2009-06-04
EP1431311B1 (en) 2016-07-20

Similar Documents

Publication Publication Date Title
CA2284829A1 (en) Immunotherapy of b-cell malignancies using anti-cd22 antibodies
CA2375912C (en) Immunotherapy of autoimmune disorders using antibodies which target b-cells
ES2543819T3 (en) Treatment of hematologic malignancies associated with circulating tumor cells using chimeric antibody directed against CD20
US5686072A (en) Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
JP2010031032A5 (en)
Cameron et al. Obinutuzumab: first global approval
JP2006514024A5 (en)
RU2007134368A (en) METHODS FOR TREATING LYMPHOMAS USING A COMBINATION OF CHEMOTHERAPEUTIC AND IL-2, AND, NOT MANDATORY, ANTIBODY ANTI-CD20
MD1367B2 (en) Methods of B-cells lymphoma treatment, anti-CD20 antibodies, hybridoma
CA2501757A1 (en) Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents
Hamblin et al. Initial experience in treating human lymphoma with a chimeric univalent derivative of monoclonal anti-idiotype antibody
Stevenson et al. Treatment of lymphoid tumors with anti-idiotype antibodies
Scheinberg Current applications of monoclonal antibodies for the therapy of hematopoietic cancers
Awwad et al. Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions
Liu et al. The potential for immunoconjugates in lymphoma therapy
Foon Biological therapy of cancer
EP1543839B1 (en) Immunotherapy of autoimmune disorders using antibodies which target B-cells
Lowder et al. Suppression of anti-mouse immunoglobulin antibodies in subhuman primates receiving murine monoclonal antibodies against T cell antigens.
JPWO2021202770A5 (en)
Juliusson et al. Mechanisms behind hypocholesterolaemia in hairy cell leukaemia.
May Single-Agent Odronextamab Produces Durable Responses in CD20-Positive B-Cell Malignancies
US20200283539A1 (en) Combination therapy for treatment of a hematological disease
Maloney Factors leading to rituximab resistance and how to overcome them
Foon Treatment of Leukemia and Lymphoma with Biological Response Modifiers
JPWO2021138264A5 (en)

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20180319